UCLA Cardiac Arrhythmia Center, UCLA Health System, David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suite 660, Los Angeles, CA, USA.
UCLA Cardiac Arrhythmia Center, UCLA Health System, David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suite 660, Los Angeles, CA, USA.
Trends Cardiovasc Med. 2019 Oct;29(7):394-400. doi: 10.1016/j.tcm.2018.11.002. Epub 2018 Nov 6.
Sudden cardiac arrest is the leading cause of cardiovascular mortality, posing a substantial public health burden. The incidence and epidemiology of sudden death are a function of age, with primary arrhythmia syndromes and inherited cardiomyopathies representing the predominant causes in younger patients, while coronary artery disease being the leading etiology in those who are 35 years of age and older. Internal cardioverter defibrillators remain the mainstay of primary and secondary prevention of sudden cardiac arrest. In the acute phase, cardiac chain of survival, early reperfusion, and therapeutic hypothermia are the key steps in improving outcomes. In the chronic settings, ventricular tachycardia ablation has been shown to improve patients' quality of life by reducing frequency of defibrillator shocks. Moreover, recent studies have suggested that it may increase survival. Neuromodulation represents a novel therapeutic modality that has a great potential for improving treatment of ventricular arrhythmias.
心脏性猝死是心血管疾病死亡的主要原因,给公共健康带来了巨大负担。心源性猝死的发生率和流行病学特点与年龄有关,主要心律失常综合征和遗传性心肌病在年轻患者中更为常见,而 35 岁及以上患者的主要病因是冠状动脉疾病。体内除颤器仍然是预防心脏性猝死的主要方法。在急性期,心脏生存链、早期再灌注和治疗性低温是改善预后的关键步骤。在慢性期,室性心动过速消融术通过减少除颤器电击次数来提高患者的生活质量。此外,最近的研究表明,它可能提高生存率。神经调节是一种新的治疗方法,对改善室性心律失常的治疗有很大的潜力。